Mamazol Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole functions by inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens, thereby reducing estrogen levels in the body. This reduction in estrogen helps to slow or reverse the growth of estrogen-dependent breast cancer cells. Mamazol is indicated for adjuvant treatment of early breast cancer, as well as for advanced or metastatic breast cancer in postmenopausal women. It is also employed in ovulation induction protocols for women with anovulatory infertility. The recommended dosage is typically one 2.5 mg tablet taken orally once daily, with or without food, as directed by a healthcare professional. Common adverse effects may include hot flashes, fatigue, dizziness, arthralgia, and nausea. Caution is advised in patients with hepatic impairment, and it is contraindicated in premenopausal women and during pregnancy or lactation. Regular monitoring of bone mineral density and lipid profiles is recommended during prolonged therapy. Mamazol should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.